Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 20/20 | 0.73 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.73 |
| ▸ | FLT3 | P36888 | 3/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | KIT | P10721 | 2/20 | 0.73 |
| ▸ | LCK | P06239 | 1/20 | 0.73 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.73 |
| ▸ | KDR | P35968 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16045800 | 1.00 | CSF1R (0.73) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL31740343 | 0.90 | CSF1R (0.57) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL31741155 | 0.89 | CSF1R (0.78) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL16046106 | 0.84 | CSF1R (0.73) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| Vimseltinib SCHEMBL30453793 | 0.84 | CSF1R (1.00) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| Vimseltinib SCHEMBL16047448 | 0.84 | CSF1R (1.00) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL31740888 | 0.84 | CSF1R (0.51) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL16046817 | 0.84 | CSF1R (0.80) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| Vimseltinib SCHEMBL31615255 | 0.84 | CSF1R (0.98) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL30562950 | 0.83 | CSF1R (0.51) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078107-A1 | CSF-1R INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-03-19 | — | — | US | disclosed |
| CN-118453610-A | CSF1R inhibitors for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-118453608-A | CSF1R inhibitors for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-118453609-A | CSF1R inhibitors for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-113453684-B | CSF1R inhibitors for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-05-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078107-A1 | CSF-1R INHIBITORS AND METHODS OF USE THEREOF | CSF1R, CSF3R, FLT3 | CSF1R 1/4885PDGFRA 123/4885PDGFRB 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.